R

Robert J. Glynn

Brigham and Women's Hospital

25 papers and 17k citations.

PubIndex Score99Top 1% · mid-careerHow it's scored

🌱#1 Emerging Leader in Atherosclerosis and Cardiovascular Diseases 🌱#1 Emerging Leader in Inflammasome and immune disorders 🌱#2 Emerging Leader in Adipokines, Inflammation, and Metabolic Diseases 🌱#6 Emerging Leader in Venous Thromboembolism Diagnosis and Management

25Publications

17kTotal Citations

#1in Atherosclerosis and Cardiovascular Diseases

First publication: 1997First senior author: 2017

Top publicationsby citations

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Paul M. Ridker, Robert J. Glynn, José Carlos Nicolau et al.|New England Journal of Medicine|2017

Cited by 9.1k

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Paul M. Ridker, Hakan Kültürsay, Jean MacFadyen et al.|The Lancet|2017

Cited by 1.3k

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

Paul M. Ridker, Robert J. Glynn, Samuel Z. Goldhaber et al.|New England Journal of Medicine|2003

Cited by 809

Indexing the rest of 25 publications…